Urogen Pharma Ltd- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Urogen Pharma Ltd 公司

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Urogen Pharma Ltd簡介



公司代碼URGN

公司名稱Urogen Pharma Ltd

上市日期May 04, 2017

CEOBarrett (Elizabeth A)

員工數量235

證券類型Ordinary Share

年結日May 04

公司地址9 Ha'ta'asiya St

城市RA'ANANA

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Israel

郵編4365007

電話97297707601

網址https://www.urogen.com/

公司代碼URGN

上市日期May 04, 2017

CEOBarrett (Elizabeth A)

Urogen Pharma Ltd公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Arie S. Belldegrun, M.D.

Independent Chairman of the Board

408.69K

--

Ms. Elizabeth A. (Liz) Barrett

President, Chief Executive Officer, Director

326.69K

--

Mr. Jason Drew Smith

Chief Compliance Officer, General Counsel, Corporate Secretary

43.30K

+1813.00%

Mr. Christopher (Chris) Degnan

Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer

2.28K

+2280.00%

Ms. Cynthia M. Butitta

Independent Director

2.00K

+2000.00%

Dr. Stuart Holden, M.D.

Independent Director

--

Dr. Mark P. Schoenberg, M.D.

Chief Medical Officer

--

Mr. Vincent Perrone

Investor Relations

--

Dr. Leana S. Wen, M.D.

Independent Director

--

Mr. Daniel G. Wildman

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Arie S. Belldegrun, M.D.

Independent Chairman of the Board

408.69K

--

Ms. Elizabeth A. (Liz) Barrett

President, Chief Executive Officer, Director

326.69K

--

Mr. Jason Drew Smith

Chief Compliance Officer, General Counsel, Corporate Secretary

43.30K

+1813.00%

Mr. Christopher (Chris) Degnan

Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer

2.28K

+2280.00%

Ms. Cynthia M. Butitta

Independent Director

2.00K

+2000.00%

Dr. Stuart Holden, M.D.

Independent Director

--

收入明細

單位: USD更新時間: 1月6日週二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

業務USD

名稱

營收

佔比

Jelmyto

25.70M

93.53%

Zusduri

1.78M

6.47%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

Jelmyto

25.70M

93.53%

Zusduri

1.78M

6.47%

股東統計

更新時間: 2月7日週六

持股股東

股東類型

持股股東

佔比

RTW Investments L.P.

9.71%

Paradigm BioCapital Advisors LP

9.01%

TD Securities, Inc.

6.82%

Morgan Stanley & Co. LLC

5.25%

Jefferies LLC

4.70%

其他

64.52%

持股股東

佔比

RTW Investments L.P.

9.71%

Paradigm BioCapital Advisors LP

9.01%

TD Securities, Inc.

6.82%

Morgan Stanley & Co. LLC

5.25%

Jefferies LLC

4.70%

其他

64.52%

股東類型

持股股東

佔比

Hedge Fund

29.37%

Research Firm

22.98%

Investment Advisor

22.01%

Investment Advisor/Hedge Fund

19.50%

Insurance Company

4.14%

Individual Investor

2.09%

Corporation

1.79%

Private Equity

1.47%

Bank and Trust

0.25%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

321

48.31M

103.21%

-13.86M

2025Q3

311

45.66M

97.55%

-6.58M

2025Q2

285

53.00M

114.72%

+5.27M

2025Q1

290

49.25M

108.64%

+1.67M

2024Q4

280

43.94M

103.24%

-1.94M

2024Q3

262

44.13M

104.63%

-2.19M

2024Q2

247

46.02M

111.40%

+11.07M

2024Q1

255

34.96M

99.86%

+5.57M

2023Q4

237

29.16M

94.80%

+4.33M

2023Q3

238

25.93M

86.41%

+2.69M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

RTW Investments L.P.

4.54M

9.71%

--

Sep 30, 2025

Paradigm BioCapital Advisors LP

4.22M

9.01%

+1.88M

+80.79%

Sep 30, 2025

TD Securities, Inc.

3.19M

6.82%

--

Sep 30, 2025

Morgan Stanley & Co. LLC

2.46M

5.25%

+983.01K

+66.65%

Sep 30, 2025

Jefferies LLC

2.20M

4.7%

--

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

2.14M

4.58%

+33.75K

+1.60%

Sep 30, 2025

SilverArc Capital Management, LLC

1.58M

3.37%

-445.20K

-22.01%

Sep 30, 2025

Millennium Management LLC

1.47M

3.14%

+874.71K

+147.25%

Sep 30, 2025

UBS Asset Management Switzerland AG

1.32M

2.82%

--

Jan 31, 2025

Acorn Capital Advisors, LLC

1.26M

2.69%

--

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

ARK Israel Innovative Technology ETF

2.09%

Tema Oncology ETF

1.92%

ALPS Medical Breakthroughs ETF

0.39%

Hypatia Women CEO ETF

0.28%

ProShares Ultra Nasdaq Biotechnology

0.16%

iShares Micro-Cap ETF

0.15%

Fidelity Enhanced Small Cap ETF

0.11%

Vanguard US Momentum Factor ETF

0.1%

Invesco Nasdaq Biotechnology ETF

0.09%

iShares Biotechnology ETF

0.07%

ARK Israel Innovative Technology ETF

佔比2.09%

Tema Oncology ETF

佔比1.92%

ALPS Medical Breakthroughs ETF

佔比0.39%

Hypatia Women CEO ETF

佔比0.28%

ProShares Ultra Nasdaq Biotechnology

佔比0.16%

iShares Micro-Cap ETF

佔比0.15%

Fidelity Enhanced Small Cap ETF

佔比0.11%

Vanguard US Momentum Factor ETF

佔比0.1%

Invesco Nasdaq Biotechnology ETF

佔比0.09%

iShares Biotechnology ETF

佔比0.07%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據